|
Abdominoplasty/Apronectomy (following significant weight loss) Referral proforma PP45 (Saesneg) (Word, 92Kb)
|
|
Abdominoplasty/Apronectomy following Significant Weight Loss, Policy Position Statement (PP45), March 2025 (Saesneg) (PDF, 145Kb)
|
|
Adult Congenital Heart Disease Services (Levels 1 and 2) for people aged 16 and over, Service Specification (CP214). June 2022 (Saesneg) (PDF, 423Kb)
|
|
Adult Neurosurgery, Service Specification, (CP178), March 2023 (Saesneg) (PDF, 731Kb)
|
|
Adult Thoracic Surgery, Service Specification (CP144), September 2020 (Saesneg) (PDF, 450Kb)
|
|
All Wales Posture and Mobility, Service Specification (CP59). April 2017 (Saesneg) (PDF, 1.5Mb)
|
|
Allogeneic Haematopoietic Stem Cell Transplant (HSCT) for people of all ages with Sickle Cell Disease (SCD), Commissioning Policy (CP224). November 2021 (Saesneg) (PDF, 443Kb)
|
|
Alternative and Augmentative Communication (AAC), Commissioning Policy (CP93), May 2019 (Saesneg) (PDF, 371Kb)
|
|
Asfotase alfa for treating paediatric-onset hypophosphatasia in children aged under 16 years, Policy Position Statement (PP156), November 2023 (Saesneg) (PDF, 263Kb)
|
|
Ataluren for Treating Duchenne Muscular Dystrophy with a Nonsense Mutation in the Dystrophin Gene Policy Position Statement (PP118), July 2023 (Saesneg) (PDF, 217Kb)
|
|
Atidarsagene Autotemcel for Treating Metachromatic Leukodystrophy in Children, Policy Position Statement, (PP257), April 2023 (Saesneg) (PDF, 180Kb)
|
|
Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension (all ages), Policy Position Statement (PP162), January 2019 (Saesneg) (PDF, 274Kb)
|
|
Berotralstat for preventing recurrent attacks of hereditary angioedema for people aged 12 years and older, Policy Position Statement (PP236). June 2022 (Saesneg) (PDF, 277Kb)
|
|
Bevacizumab for the treatment of vestibular schwannomas in Neurofibromatosis Type 2 (now known as NF2-related vestibular schwannomatosis) (all ages) (CP254), August 2023 (Saesneg) (PDF, 440Kb)
|
|
Birch bark extract for treating epidermolysis bullosa in people aged 6 months and older, Policy Position Statement (PPS284), December 2024 (Saesneg) (PDF, 398Kb)
|
|
Bleeding Disorders (All Ages), Service Specification (CP77), June 2022 (Saesneg) (PDF, 343Kb)
|
|
Body Contouring, Commissioning Policy (CP44). March 2025 (Saesneg) (PDF, 293Kb)
|
|
Breast Surgery Procedures, Commissioning Policy (CP69). March 2025 (Saesneg) (PDF, 251Kb)
|
|
Burosumab for Treating X-linked Hypophosphataemia in Children and Young People, Policy Position (PP177), May 2019 (Saesneg) (PDF, 557Kb)
|
|
Canakinumab for treating periodic fever syndromes: TRAPS, HIDS/MKD and FMF (ages 2 and older), Policy Position Statement, (PP228). January 2022 (Saesneg) (PDF, 324Kb)
|
|
Cannabidiol for treating seizures caused by tuberous sclerosis complex in people aged 2 years and above (PP272) December 2026 (Saesneg) (PDF, 249Kb)
|
|
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in people aged 2 years and older, Policy Position Statement (PP203), July 2024 (Saesneg) (PDF, 388Kb)
|
|
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 for children aged under 16 years, Policy Position Statement (PP262), November 2023 (Saesneg) (PDF, 233Kb)
|
|
Chimeric Antigen Receptor T Cell (CAR T) Therapy, Gilead Axicabtagene Ciloleucel (Yescarta®) Service Specification (CP175), March 2019 (Saesneg) (PDF, 514Kb)
|
|
Chimeric Antigen Receptor T Cell (CAR T) Therapy, Novartis Tisagenlecleucel (Kymriah ®) Service Specification, (CP176), March 2019 (Saesneg) (PDF, 571Kb)
|
|
Chimeric Antigen Receptor T Cell (CAR T) Therapy, Policy Position Statement, (PP185). April 2023 (Saesneg) (PDF, 254Kb)
|
|
Circumcision for Children, Commissioning Policy, (CP34). December 2024 (Saesneg) (PDF, 344Kb)
|
|
Cleft Lip and/or Palate including Non-Cleft Velopharyngael Dysfuncion: All Ages, Service Specification (CP186), November 2025 (Saesneg) (PDF, 591Kb)
|
|
Complex Devices: Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure, Policy Position Statement (PP151), January 2019 (Saesneg) (PDF, 299Kb)
|
|
Corneal cross-linking for keratoconus in children (from birth until their 16th birthday) commissioning policy, (CP271), October 2023 (Saesneg) (PDF, 328Kb)
|
|
CP01, Brachytherapy for the treatment of localised prostate cancer, Commissioning Policy, November 2024 (Saesneg) (PDF, 540Kb)
|
|
CP101, Intra-arterial adjunct devices adults and young people (aged 16 and over), Commissioning Policy, November 2024 (Saesneg) (PDF, 459Kb)
|
|
CP247, Autologous haematopoietic stem cell transplantation for people aged 18 years and over with previously treated relapsing multiple sclerosis, Commissioning Policy, November 2024 (Saesneg) (PDF, 523Kb)
|
|
Crizanlizumab for Preventing Sickle Cell Crisis in Sickle Cell Disease (SCD) in people aged 16 and over, Policy Position Statement (PP234), February 2023 (Saesneg) (PDF, 281Kb)
|
|
Cystic Fibrosis Modulator therapies Policy Position Statement, (PP198). March 2022 (Saesneg) (PDF, 354Kb)
|
|
Cystic Fibrosis: Adults and Young People (CP193), Service Specification Jan 2025 (Saesneg) (PDF, 391Kb)
|
|
Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis and Pseudomyxoma Peritonei, Policy Position Statement, (PP90). September 2015 (Saesneg) (PDF, 239Kb)
|
|
Deep Brain Stimulation, Commissioning Policy (CP28), July 2024 (Saesneg) (PDF, 384Kb)
|
|
Dexrazoxane for Preventing Cardiotoxicity in Children (Aged Under 16 Years Old) Receiving High-Dose Anthracyclines or Related Drugs for the Treatment of Cancer, Policy Position Statement (PP253), February 2023 (PDF, 265Kb)
|
|
Dialysis Away from Base (DAFB) (Holiday Dialysis) (CP33) December 2024 (Saesneg) (Word, 205Kb)
|
|
Drug Treatment for Lysosomal Storage Disorders (All Ages), Commissioning Policy (CP55), October 2024 (Saesneg) (PDF, 696Kb)
|
|
Eating Disorder Outreach Service (EDOS) (for people aged under 18 years) Service Specification (SS295), August 2024 (Seasneg) (PDF, 560Kb)
|
|
Eculizimab for Atypical Haemolytic Uraemic Syndrome (aHUS), (CP98), November 2025 (Saesneg) (PDF, 284Kb)
|
|
Eculizumab for Paroxysmal Nocturnal Haemoglobinuria, Commissioning Policy (CP152), July 2024 (Saesneg) (PDF, 778Kb)
|
|
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (PP281) February 2027 (Saesneg) (PDF, 212Kb)
|
|
Electrophysiology and Ablation Services (16 years and older), Commissioning policy (CP197a) January 2025 (Saesneg) (PDF, 347Kb)
|
|
Electrophysiology and Ablation Services (16 years and older), Service Specification (CP197b) January 2025 (Saesneg) (PDF, 331Kb)
|
|
Emicizumab as prophylaxis in people with congenital haemophilia A with Factor VIII inhibitors (all ages), Policy Position Statement (PP167). November 2018 (Saesneg) (PDF, 316Kb)
|
|
Emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors, Policy Position Statement, (PP189), November 2023 (Saesneg) (PDF, 288Kb)
|
|
Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex (aged 2 years and above) (PP250) December 2026 (Saesneg) (PDF, 258Kb)
|
|
Everolimus for renal angiomyolipoma associated with tuberous sclerosis complex (TSC) in adults (PP274) December 2026 (Saesneg) (PDF, 332Kb)
|
|
Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) (all ages) (PP273) December 2026 (Saesneg) (PDF, 335Kb)
|
|
Everolimus for the prevention of organ rejection following heart transplantation, Policy Position Statement (PP103), July 2019 (Saesneg) (PDF, 164Kb)
|
|
Extra corporeal membrane oxygenation (ECMO) service for adults with cardiac failure, Policy Position Statement, (PP102). July 2019 (Saesneg) (PDF, 141Kb)
|
|
Extracorporeal Membrane Oxygenation (ECMO) as a Bridge to Lung Transplant (BTLT) (All Ages), Policy Position Statement, (PP251), February 2023 (Saesneg) (PDF, 141Kb)
|
|
Specialised Services Policy: Extracorporeal Photophoresis (ECP) for the Treatment of Chronic Graft versus Host Disease in Adults (CP91), November 2015 (Saesneg) (PDF, 658Kb)
|
|
Extracorporeal Photophoresis (ECP) for the treatment of cutaneous T-cell lymphoma, Commissioning Policy (CP92), November 2015 (Saesneg) (PDF, 683Kb)
|
|
Facial Surgery procedures, Commissioning Policy (CP43). March 2025 (Saesneg) (PDF, 325Kb)
|
|
Facial Surgery procedures: Referral proforma Blepharoplasty (CP43) (Saesneg) (Word, 92Kb)
|
|
Facial Surgery procedures: Referral proforma Face lift/brow lift (CP43) (Saesneg) (Word, 92Kb)
|
|
Facial Surgery procedures: Referral proforma Miscellaneous (CP43) (Saesneg) (Word, 91Kb)
|
|
Facial Surgery procedures: Referral proforma Pinnaplasty (CP43) (Saesneg) (Word, 91Kb)
|
|
Facial Surgery procedures: Referral proforma Rhinoplasty (CP43) (Saesneg) (Word, 92Kb)
|
|
Gatekeeping, Placement and Case Management for Specialised Mental Health Services (CP232) June 2022 (Saesneg) (PDF, 399Kb)
|
|
Gender Identity Service for Adults (non surgical) Commissioning Policy (CP182a) July 2024 (Saesneg) (PDF, 543Kb)
|
|
Gender Identity Service for Adults (non surgical) Service Specification (CP182b) July 2024 (Saesneg) (PDF, 578Kb)
|
|
Genomic Services, Service Specification (CP99), June 2022 (Saesneg) (PDF, 572Kb)
|
|
Genomic Testing, Policy Position Statement, (PP184). June 2020 (Saesneg) (PDF, 231Kb)
|
|
Givosiran for Treating Acute Hepatic Porphyria for People Aged 12 Years and Older, Policy Position Statement, (PP252), April 2023 (Saesneg) (PDF, 131Kb)
|
|
Gwasanaethau hunaniaeth o ran rywedd i blant a phobl ifanc arbenigol GIG Cymru (PDF, 1.7Mb)
|
|
Haematopoietic stem cell transplantation for adults, Service Specification (CP79). January 2020 (Saesneg) (PDF, 295Kb)
|
|
Haematopoietic stem cell transplantation, Policy Position Statement, (PP142). January 2020 (Saesneg) (PDF, 553Kb)
|
|
Hepatobiliary Surgery, Service Specification (CP73), June 2021 (Saesneg) (PDF, 318Kb)
|
|
Home administered Parenteral Nutrition (HPN), Commissioning Policy (CP24). August 2014 (Saesneg) (PDF, 202Kb)
|
|
Hyperbaric Oxygen Therapy, Commissioning Policy (CP07), July 2023 (Saesneg) (PDF, 363Kb)
|
|
Inherited White Matter Disorders Policy Position Statement (PP239) May 2023 (Saesneg) (PDF, 565Kb)
|
|
In-patient Child and Adolescent Mental Health Services (CAMHS): General Adolescent (GAU) and Extra Care Area (ECA), Service Specification (CP150), November 2026 (Saesneg) (PDF, 547Kb)
|
|
Living Donor Expenses, Commissioning Policy (CP30), December 2026 (Saesneg) (PDF, 307Kb)
|
|
Lumasiran for treating primary hyperoxaluria type 1, Policy Position Statement (PP277), December 2026 (Saesneg)
|
|
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (NETs), Policy Position Statement (PP195), November 2026 (Saesneg) (PDF, 334Kb)
|
|
Lymphovenous Anastamosis (LVA) microsurgery for primary and secondary lymphoedema, Commissioning Policy (CP87b), August 2015 (Saesneg) (PDF, 918Kb)
|
|
Lymphovenous Anastamosis (LVA) microsurgery for primary and secondary lymphoedema, Service Specification (CP87a), August 2015 (Saesneg) (PDF, 817Kb)
|
|
Major Trauma Centre, Appendix 1, Commissioning & governance arrangements for partner organisations within the Major Trauma Network. (CP188) February 2021 (Saesneg) (PDF, 345Kb)
|
|
Major Trauma Centre, Appendix 2: Quality Indicators. (CP188) February 2021 (Saesneg) (PDF, 1.1Mb)
|
|
Major Trauma Centre, Service Specification (CP188), February 2021 (Saesneg) (PDF, 665Kb)
|
|
Mechanical Thrombectomy for the treatment of acute Ischaemic Stroke, Commissioning Policy (CP168). March 2025 (Saesneg) (PDF, 887Kb)
|
|
Microprocessor controlled prosthetic knees (CP218), Commissioning Policy, December 2021 (Saesneg) (PDF, 363Kb)
|
|
National Acute Porphyria, Service Specification (CP166). February 2025 (Saesneg) (PDF, 274Kb)
|
|
Neonatal Services (Intensive Care, High Dependency and Special Care) (CP263) August 2024 (Saesneg) (PDF, 481Kb)
|
|
Neonatal Services (Intensive Care, High Dependency and Special Care) (SS263) August 2024 (Saesneg) (PDF, 591Kb)
|
|
New Treatment Fund (CP159) January 2025 (Saesneg) (PDF, 354Kb)
|
|
Nusinersen for treating spinal muscular atrophy, Policy Position Statement (PP191), November 2026 (Saesneg) (PDF, 400Kb)
|
|
Obesity Surgery for Complex and Severe Obesity Level 4 (Adults), Commissioning Policy, (CP29a), March 2023 (Saesneg) (PDF, 316Kb)
|
|
Obesity Surgery for Complex and Severe Obesity- Level 4 (Adults), Service Specification (CP29b), March 2023 (Saesneg) (PDF, 383Kb)
|
|
Odevixibat for Treating Progressive Familial Intrahepatic Cholestasis, Policy Position Statement, (PP249), February 2023 (Saesneg) (PDF, 193Kb)
|
|
Paediatric Endocrinology, Service Specification (CP163), July 2024 (Saesneg) (PDF, 283Kb)
|
|
Paediatric Nephrology, Service Specification (CP169), March 2021 (Saesneg) (PDF, 418Kb)
|
|
Pasireotide for Cushing's Disease, Policy Position (PP155), July 2019 (Saesneg) (PDF, 252Kb)
|
|
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors (NET) in Adults, Service Specification, (CP266), March 2023 (Saesneg) (PDF, 300Kb)
|
|
Percutaneous Mitral Valve Leaflet repair for primary degenerative mitral regurgitation in adults, Policy Position Statement (PP206). June 2021 (Saesneg) (PDF, 195Kb)
|
|
Perinatal post-mortem investigation of fetal and neonatal deaths (England, Scotland and Wales). Interim Clinical Commissioning Urgent Policy Statement. October 2022 (PDF, 304Kb)
|
|
Personalised External Aortic Root Support (PEARS) for surgical management of enlarged aortic root (adults), Policy Position Statement, (PP104). March 2025 (Saesneg) (PDF, 195Kb)
|
|
Plerixafor for stem cell mobilisation, Policy Position Statement (PP154), July 2024 (Saesneg) (PDF, 208Kb)
|
|
Positron Emission Tomography (PET) (CP50), Commissioning Policy, April 2024 (Saesneg) (PDF, 488Kb)
|
|
Positron Emission Tomography (PET), Service Specification (CP50b). September 2020 (Saesneg) (PDF, 514Kb)
|
|
Preimplantation Genetic Diagnosis (PGD), Commissioning Policy (CP37). March 2025 (Saesneg) (PDF, 445Kb)
|
|
Prosthetic Provision, Service Specification (CP89). March 2025 (Saesneg) (PDF, 433Kb)
|
|
Proton Beam Therapy for adults with cancer Commissioning Policy (CP147), July 2023 (Saesneg) (PDF, 279Kb)
|
|
Proton Beam Therapy for children, teenagers and young adults (TYA) with cancer, Commissioning Policy (CP148), April 2023 (Saesneg) (PDF, 231Kb)
|
|
Radiofrequency Ablation (RFA) for the Management of Barrett's Oesophagus, Commissioning Policy (CP183a). May 2020 (Saesneg) (PDF, 318Kb)
|
|
Radiofrequency Ablation (RFA) for the Management of Barrett's Oesophagus, Service Specification (CP183b). May 2020 (Saesneg) (PDF, 348Kb)
|
|
Recreational and Sport Prosthetics for people under the age of 25 (CP221), Commissioning Policy, November 2021 (Saesneg) (PDF, 376Kb)
|
|
Revision Surgery for Severe and Complex Obesity (Adults) (CP259), Commissioning Policy, May 2023 (Saesneg) (PDF, 406Kb)
|
|
Risdiplam for Spinal Muscular Atrophy for people aged under 16 years, Policy Position Statement (PP240). May 2022 (Saesneg) (PDF, 361Kb)
|
|
Rituximab and Eculizumab for the Prevention and Management of Delayed Haemolytic Transfusion Reactions and Hyperhaemolysis in people with Hereditary Anaemias, Policy Position Statement (PP237), February 2023 (PDF, 438Kb)
|
|
Salvage Cryotherapy for Prostate Cancer, Policy Position Statement, (PP173). June 2020 (Saesneg) (PDF, 188Kb)
|
|
Sapropterin for treating hyperphenylalaninaemia (HPA) in phenylketonuria (PKU) and tetrahydrobiopterin (BH4) disorders, Policy Position (PP223), January 2023 (Saesneg) (PDF, 464Kb)
|
|
Selective Dorsal Rhizotomy (SDR) for the treatment of spasticity in cerebral palsy in children aged 3-9 years, Policy Position Statement (PP245), March 2024 (Saesneg) (PDF, 975Kb)
|
|
Selective internal radiation therapies (SIRT) for treating adults with hepatocellular carcinoma (PPS227), Policy Position Statement, November 2021 (Saesneg) (PDF, 276Kb)
|
|
Selexipag for the Treatment of Pulmonary Arterial Hypertension (Adults), Policy Position (PP105), March 2019 (Saesneg) (PDF, 255Kb)
|
|
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over, Policy Position Statement (PP267), September 2023 (Saesneg) (PDF, 228Kb)
|
|
Services for Children with Cancer, Service Specification (SS86), December 2024 (Saesneg) (PDF, 509Kb)
|
|
Sickle Cell Disorders, Thalassaemia Disorders and other rare hereditary anaemias: all ages, Service Specification (CP179), December 2020 (Saesneg) (PDF, 453Kb)
|
|
Soft Tissue Sarcoma, Service Specification (CP149), May 2020 (Saesneg) (PDF, 410Kb)
|
|
Specialised Fetal Medicine, Commissioning Policy, (CP97), October 2023 (Saesneg) (PDF, 372Kb)
|
|
Specialised Immunology, Service Specification (SS78), October 2024 (Saesneg) (PDF, 615Kb)
|
|
Specialised Neurological Rehabilitation, Commissioning Policy (CP140), February 2018 (Saesneg) (PDF, 474Kb)
|
|
Specialised Neuropsychiatric Rehabilitation, Commissioning Policy (CP128), February 2018 (Saesneg) (PDF, 523Kb)
|
|
Specialised Paediatric Gastroenterology, Hepatology and Nutrition (PGHAN) (CP211) May 2023 (Saesneg) (PDF, 759Kb)
|
|
Specialised Paediatric Neurological Rehabilitation, Commissioning Policy (CP160), November 2024 (Saesneg) (PDF, 385Kb)
|
|
Specialised Paediatric Rheumatology Service, Service Specification (CP172), November 2021 (Saesneg) (PDF, 448Kb)
|
|
Specialised Services Clinical Access Policy: Enhanced Image Guided Brachytherapy (IGBT) Service for the Treatment of Gynaecological Malignancies (CP75), May 2017 (Saesneg) (PDF, 755Kb)
|
|
Specialised Spinal Cord Injury Rehabilitation, Commissioning Policy (CP141), February 2018 (Saesneg) (PDF, 418Kb)
|
|
Specialist Fertility Services, Commissioning Policy (CP38), April 2025 (Saesneg) (PDF, 360Kb)
|
|
Specialist Perinatal Mental Health Inpatient Service (Mother and Baby Unit) (CP201), Service Specification, April 2021 (Saesneg) (PDF, 451Kb)
|
|
Spinal Services Operational Delivery Network (CP241) June 2022 (Saesneg) (PDF, 381Kb)
|
|
SS235, Specialist Auditory Hearing Implant Service (all ages), Service Specification, November 2024 (Saesneg) (PDF, 684Kb)
|
|
Stereotactic ablative body radiotherapy (SABR) for patients aged 18 years old and above (PP278) August 2026 (Saesneg) (PDF, 511Kb)
|
|
Stereotactic ablative body radiotherapy (SABR) for patients aged 18 years old and above with (LANPC) (PP280) August 2026 (Saesneg) (PDF, 371Kb)
|
|
Stereotactic Ablative Body Radiotherapy (SABR) for patients with metachronous extracranial oligometastic cancer (all ages), Commissioning Policy (CP121), December 2024 (Saesneg) (PDF, 551Kb)
|
|
Stereotactic Ablative Body Radiotherapy (SABR) for the management of Non-Small Cell Lung Cancer in people aged 18 years and above, Commissioning Policy (CP76) June 2023 (PDF, 525Kb)
|
|
Stereotactic Ablative Body Radiotherapy (SABR), Service Specification (SS219), December 2024 (saesneg) (PDF, 505Kb)
|
|
Stereotactic Ablative Radiotherapy (SABR) for patients with hepatocellular carcinoma (HCC) (adults), Commissioning Policy, (CP124), December 2024 (Saesneg) (PDF, 550Kb)
|
|
Stereotactic Ablative Radiotherapy (SABR) for people aged 18 years old and above with primary kidney cancer, Commissioning Policy (CP279), June 2024 (PDF, 512Kb)
|
|
Stereotactic Radiosurgery for Adults, Teenagers and Young Adults (TYA) (CP22) June 2026 (Saesneg) (PDF, 455Kb)
|
|
Tier 4 Forensic Child and Adolescent Mental Health Service (Forensic Adolescent Consultation Service – Consultation and Advice for Child and Adolescent Mental Health Services), Service Specification, (CP222), August 2023 (Saesneg) (PDF, 523Kb)
|
|
Tier 4 Specialised Eating Disorder Services, Commissioning Policy (CP20), November 2011 (Saesneg) (PDF, 819Kb)
|
|
Tofacitinib for treating juvenile idiopathic arthritis in people aged 2 to 16 years, Policy Position Statement (PP229). May 2022 (Saesneg) (PDF, 311Kb)
|
|
Trans-catheter Aortic Valve Implantation (TAVI) for Severe Symptomatic Aortic Stenosis (SSAS), Commissioning Policy (CP58), March 2019 (PDF, 295Kb)
|
|
Transcranial magnetic resonance guided focused ultrasound (TcMRgFUS) thalamotomy for treatment of medication-refractory essential tremor for people aged 18 and over, Policy Position Statement, (PP258), August 2023 (Saesneg) (PDF, 298Kb)
|
|
Trauma Operational Delivery Network (CP199), Service Specification, February 2021 (Saesneg) (PDF, 638Kb)
|
|
Treatment of Benign Skin Conditions, Commissioning Policy (CP42). March 2025 (Saesneg) (PDF, 291Kb)
|
|
Treatment of Benign Skin Conditions, Referral Proforma Resurfacing (CP42) (Saesneg) (PDF, 355Kb)
|
|
Treatment options for Transthyretin Amyloidosis in Adults, Policy Position Statement (PP187), September 2023 (Saesneg) (PDF, 307Kb)
|
|
Vagal Nerve Stimulation, Commissioning Policy (CP23), July 2023 (Saesneg) (PDF, 688Kb)
|
|
Volanesorsen for treating familial chylomicronaemia syndrome, Policy Position Statement, (PP217). October 2021 (Saesneg) (PDF, 285Kb)
|
|
Vonicog alfa for the treatment and prevention of bleeding in people of all ages with von Willebrand disease, Policy Position Statement (PP215) (Saesneg) (PDF, 353Kb)
|
|
Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations (PP196), March 2020 (Saesneg) (PDF, 277Kb)
|
|
War Veterans – Enhanced Prosthetic Provision, Commissioning Policy (CP40), October 2020 (Saesneg) (PDF, 408Kb)
|
|
Welsh Artificial Eye Service (WAES) (All Ages), Service Specification (CP238), December 2022 (Saesneg) (PDF, 453Kb)
|